Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases.
Angitia Biopharmaceuticals has raised $130.0M in total funding. The most recent round was Series D. The last funding was announced in February 2026.
Angitia Biopharmaceuticals's investors include RA Capital Management, BlackRock, Hillhouse Investment, Legend Capital, Janus Henderson Investors.
Angitia Biopharmaceuticals is headquartered in Westlake Village, United States.
Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases.
Angitia Biopharmaceuticals is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Angitia Biopharmaceuticals — Funding & Investors." VCBacked, February 5, 2026, https://www.vcbacked.co/company/angitia-biopharmaceuticals. Accessed July 19, 2026.
VCBacked. (2026). Angitia Biopharmaceuticals — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/angitia-biopharmaceuticals
{{cite web |title=Angitia Biopharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/angitia-biopharmaceuticals |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated